Phase II study of pyrazoloacridine in metastatic renal cell carcinoma

Invest New Drugs. 2001;19(4):327-8. doi: 10.1023/a:1010622129173.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II

MeSH terms

  • Acridines / adverse effects
  • Acridines / therapeutic use*
  • Adult
  • Aged
  • Aged, 80 and over
  • Agranulocytosis / chemically induced
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / pathology
  • Drug Evaluation
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / secondary
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / secondary
  • Middle Aged
  • Nausea / chemically induced
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Thrombocytopenia / chemically induced
  • Vomiting / chemically induced

Substances

  • Acridines
  • Antineoplastic Agents
  • Pyrazoles
  • NSC 366140